+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07604571

Open-label Multi-center Study of IEV407 Alone or with Endocrine Therapy in Advanced HRHER2- Breast Cancer

Led by Novartis Pharmaceuticals · Updated on 2026-11-03

194

Participants Needed

12

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and early effects of a new drug called IEV407, both alone and combined with endocrine therapies fulvestrant or letrozole, in people with advanced hormone receptor positive HR, HER2-negative breast cancer. This is a first-in-human, open-label phase IIb study that includes a dose escalation phase followed by a dose expansion phase to find optimal dosing and assess combination treatments. The study begins with testing IEV407 alone to find the right dose. After that, combinations of IEV407 with fulvestrant or letrozole will be studied. The dose expansion phase may involve random assignment to different treatment groups if more than one option is available simultaneously. Treatments involve oral IEV407 and endocrine therapies delivered either orally or by injection, depending on the drug. Participants will be monitored for safety through assessments of side effects, laboratory tests, and dose adjustments over up to about two years. Researchers will measure toxicities, treatment interruptions, and drug levels in the blood. They will also evaluate cancer responses and progression. The study includes regular visits and evaluations to track how participants respond to the treatments over time.

CONDITIONS

Brief Title

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here